Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoplasmic Reticulum Stress | 4 | 2020 | 99 | 2.640 |
Why?
|
| Neoplasms | 8 | 2022 | 1660 | 2.060 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 595 | 2.020 |
Why?
|
| Immunotherapy | 5 | 2022 | 212 | 1.690 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2022 | 265 | 1.580 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 131 | 1.460 |
Why?
|
| Interleukin-10 | 3 | 2013 | 144 | 1.100 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 397 | 1.060 |
Why?
|
| Membrane Glycoproteins | 3 | 2017 | 370 | 1.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 91 | 0.820 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2020 | 6 | 0.780 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2020 | 14 | 0.740 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2019 | 27 | 0.710 |
Why?
|
| Protein Biosynthesis | 1 | 2020 | 181 | 0.690 |
Why?
|
| Cancer Survivors | 1 | 2020 | 145 | 0.640 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 211 | 0.640 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2015 | 199 | 0.610 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 135 | 0.570 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.570 |
Why?
|
| Mice | 12 | 2022 | 8472 | 0.560 |
Why?
|
| CD24 Antigen | 1 | 2014 | 6 | 0.500 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 29 | 0.480 |
Why?
|
| Stress, Psychological | 1 | 2020 | 824 | 0.480 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.470 |
Why?
|
| Myeloid Cells | 1 | 2014 | 57 | 0.470 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2013 | 7 | 0.460 |
Why?
|
| Embryo Loss | 1 | 2013 | 17 | 0.460 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 79 | 0.460 |
Why?
|
| Gene Deletion | 1 | 2014 | 235 | 0.460 |
Why?
|
| Poly I-C | 1 | 2013 | 20 | 0.450 |
Why?
|
| Animals | 13 | 2022 | 20877 | 0.440 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 186 | 0.440 |
Why?
|
| Pregnancy | 4 | 2013 | 2331 | 0.430 |
Why?
|
| Dendritic Cells | 1 | 2014 | 201 | 0.430 |
Why?
|
| Premature Birth | 2 | 2010 | 148 | 0.400 |
Why?
|
| Immunity | 2 | 2021 | 67 | 0.380 |
Why?
|
| Virus Diseases | 1 | 2010 | 31 | 0.380 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 56 | 0.370 |
Why?
|
| Decidua | 1 | 2010 | 8 | 0.370 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2009 | 12 | 0.360 |
Why?
|
| eIF-2 Kinase | 2 | 2020 | 49 | 0.350 |
Why?
|
| Interleukin-15 | 2 | 2020 | 66 | 0.350 |
Why?
|
| Placenta | 1 | 2010 | 101 | 0.350 |
Why?
|
| Bacterial Infections | 1 | 2010 | 163 | 0.340 |
Why?
|
| Uterus | 3 | 2013 | 77 | 0.290 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 286 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 226 | 0.240 |
Why?
|
| Humans | 14 | 2022 | 68525 | 0.230 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 17 | 0.230 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 69 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 2790 | 0.210 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2550 | 0.210 |
Why?
|
| Fetal Resorption | 2 | 2013 | 4 | 0.200 |
Why?
|
| Coculture Techniques | 2 | 2020 | 147 | 0.200 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 9 | 0.200 |
Why?
|
| Mice, Knockout | 4 | 2015 | 1692 | 0.190 |
Why?
|
| Macrophages | 3 | 2020 | 647 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 41 | 0.190 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 8 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 18 | 0.190 |
Why?
|
| Adenoma | 1 | 2021 | 132 | 0.180 |
Why?
|
| Female | 8 | 2022 | 38015 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2022 | 329 | 0.180 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 70 | 0.180 |
Why?
|
| Energy Metabolism | 1 | 2021 | 222 | 0.170 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 95 | 0.170 |
Why?
|
| Pregnancy Outcome | 2 | 2010 | 157 | 0.170 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 61 | 0.170 |
Why?
|
| Immunologic Memory | 1 | 2019 | 75 | 0.170 |
Why?
|
| Sarcoma | 1 | 2019 | 70 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1032 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 626 | 0.160 |
Why?
|
| Oxidoreductases | 1 | 2019 | 117 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1849 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 86 | 0.160 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 567 | 0.160 |
Why?
|
| Melanoma | 1 | 2022 | 335 | 0.160 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 148 | 0.160 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 13 | 0.150 |
Why?
|
| L-Selectin | 1 | 2017 | 28 | 0.150 |
Why?
|
| Glycolysis | 1 | 2017 | 79 | 0.150 |
Why?
|
| Immune Tolerance | 2 | 2015 | 114 | 0.150 |
Why?
|
| Cell Survival | 1 | 2019 | 901 | 0.150 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 499 | 0.140 |
Why?
|
| Hyaluronan Receptors | 1 | 2017 | 142 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 560 | 0.140 |
Why?
|
| Cell Line | 1 | 2019 | 1752 | 0.130 |
Why?
|
| Oxidative Stress | 1 | 2019 | 718 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 384 | 0.130 |
Why?
|
| CD11c Antigen | 1 | 2014 | 18 | 0.120 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 81 | 0.120 |
Why?
|
| Protein Engineering | 1 | 2014 | 35 | 0.120 |
Why?
|
| Tumor Escape | 1 | 2014 | 37 | 0.120 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2013 | 2 | 0.120 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2013 | 4 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 2 | 2015 | 94 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 929 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 94 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2013 | 682 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2015 | 617 | 0.090 |
Why?
|
| Chorioamnionitis | 1 | 2010 | 40 | 0.090 |
Why?
|
| Obstetric Labor, Premature | 1 | 2010 | 76 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 510 | 0.090 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 107 | 0.090 |
Why?
|
| Mice, Inbred DBA | 1 | 2010 | 120 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2019 | 2688 | 0.090 |
Why?
|
| B-Cell Activating Factor | 1 | 2009 | 12 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2009 | 145 | 0.080 |
Why?
|
| Neutrophils | 1 | 2009 | 204 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2009 | 458 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1173 | 0.060 |
Why?
|
| Inflammation | 1 | 2010 | 1030 | 0.060 |
Why?
|
| Adult | 1 | 2020 | 21375 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 30 | 0.050 |
Why?
|
| Colon | 1 | 2021 | 168 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2020 | 37 | 0.050 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 369 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 567 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 202 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 799 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 438 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 508 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 848 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 2093 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2264 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2004 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2015 | 241 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 4655 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 5719 | 0.020 |
Why?
|
| Male | 2 | 2022 | 37281 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 13 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1293 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7028 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2009 | 45 | 0.020 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2009 | 101 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 532 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 465 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 14842 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2673 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 21119 | 0.010 |
Why?
|